Business Context and Reporting Period
This Form 8-K Current Report was filed by Enanta Pharmaceuticals, Inc. on June 29, 2020. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Appointment: Mark G. Foletta was elected as an independent director.
- Board Size: The total number of directors increased to seven.
- Committee Roles: Mr. Foletta was appointed Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee.
- Term: His term expires at the 2022 annual meeting of stockholders.
Compensation and Governance Details
Mr. Foletta's compensatory arrangements include:
- Standard cash compensation for non-employee directors, including retainer fees for Board and committee service.
- A stock option to purchase 17,000 shares of Common Stock, vesting over 36 months.
- Standard indemnification agreement for non-employee directors.
Investor Verification Checklist
- Verify the impact of the new Audit Committee Chair on future financial oversight.
- Review the vesting schedule and strike price of the 17,000 share option grant in subsequent filings.
- Confirm the total number of directors remains at seven in upcoming proxy statements.